MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Synairgen enrols 120 patients for Covid treatment trial in home setting

StockMarketWire.com

Respiratory diseases focused Synairgen said it had completed the recruitment of 120 Covid-19 patients for a trial of a potential inhaled treatment in a home setting.

Results from phase-two study were expected in the second quarter of 2021.

The two-part, placebo-controlled trial involved dosing 101 patients in a hospital setting, the positive results from which were published in The Lancet Respiratory Medicine in November.

The second part involved 120 'at risk' patients in the home setting.



Story provided by StockMarketWire.com